• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24260 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Agency for Care Effectiveness (ACE) Elastomeric infusion pumps for outpatient parenteral antimicrobial therapy
2025     Agency for Care Effectiveness (ACE) Deep brain stimulators for treatment of Parkinson disease, dystonia or essential tremor
2025     Agency for Care Effectiveness (ACE) Antibacterial envelope for implantable neurostimulator infection control
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
2025     NIHR Health Technology Assessment programme Technology-enabled CONTACT tracing in care homes in the COVID-19 pandemic: the CONTACT non-randomised mixed-methods feasibility study
2025     NIHR Health Technology Assessment programme Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Non-pharmacological interventions, other than psychosocial ones, for youth aged under 18 with attention deficit/hyperactivity disorder (ADHD)]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Pharmacological treatment of migraine]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Relevance of adding vitamin-dependent rickets screening to neonatal screening]
2025     Technology Assessment at SickKids (TASK) A microcosting and cost consequence analysis from a randomized controlled trial comparing genome sequencing to exome sequencing for genetic diagnosis
2025     Agency for Care Effectiveness (ACE) EchoGo Heart Failure to aid in the diagnosis of heart failure with preserved ejection fraction
2025     Agency for Care Effectiveness (ACE) Fibresolve to aid in the diagnosis of idiopathic pulmonary fibrosis
2025     NIHR Health Technology Assessment programme High-flow nasal cannula therapy versus continuous positive airway pressure for non-invasive respiratory support in paediatric critical care: the FIRST-ABC RCTs
2025     National Institute for Health and Care Excellence (NICE) Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour. NICE interventional procedures guidance 800
2025     National Institute for Health and Care Excellence (NICE) Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal). NICE technology appraisal guidance 1052
2025     National Institute for Health and Care Excellence (NICE) Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over. NICE technology appraisal guidance 1051
2025     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over. NICE technology appraisal guidance 1054
2025     National Institute for Health and Care Excellence (NICE) Cladribine for treating active relapsing forms of multiple sclerosis. NICE technology appraisal guidance 1053
2025     National Institute for Health and Care Excellence (NICE) Relugolix–estradiol–norethisterone for treating symptoms of endometriosis. NICE technology appraisal guidance 1057
2025     National Institute for Health and Care Excellence (NICE) Molnupiravir for treating COVID-19. NICE technology appraisal guidance 1056
2025     National Institute for Health and Care Excellence (NICE) Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 1055
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1058
2025     NIHR Health and Social Care Delivery Program Opportunities and practices supporting responsive health care for forced migrants: lessons from transnational practice and a mixed-methods systematic review
2025     NIHR Health and Social Care Delivery Program Approaches used to prevent and reduce the use of restrictive practices on adults with learning disabilities: a realist review
2025     NIHR Health Technology Assessment programme A network approach to addressing the needs of patients with incurable head and neck cancer and their families
2025     NIHR Health and Social Care Delivery Program The effectiveness and cost-effectiveness of the NHS Diabetes Prevention Programme (NHS-DPP): the DIPLOMA long-term multimethod assessment
2025     Penn Medicine Center for Evidence-based Practice (CEP) Alpha-blocking medication before removal of indwelling urinary catheters
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Hospital at home in Québec healthcare institutions: considerations to support program implementation]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [New drug treatments for Alzheimer's disease: considerations for patient management]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment of mitral insufficiency with a percutaneous device with clip (TEER) in Quebec - characteristics, continuum of care and clinical outcomes of adult clientele treated between 2019-2020 and 2021-2022]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to the management of bladder cancer patients]
2025     NIHR Health and Social Care Delivery Program Optimising neonatal services for very preterm births between 27+0 and 31+6 weeks gestation in England: the OPTI-PREM mixed-methods study
2025     NIHR Health and Social Care Delivery Program Organising general practice for care homes: a multi-method study
2025     HTA South [Ultraviolet light disinfection of flexible endoscopes without working channels: a systematic review and assessment of medical, economical, and organisational aspects]
2025     NIHR Health and Social Care Delivery Program Exploring voluntary sector specialist services for victim-survivors of sexual violence in England: the PROSPER co-production study
2025     NIHR Health and Social Care Delivery Program Direct oral penicillin challenge in secondary care with low-risk patients: the SPACE mixed-methods study with cost-effectiveness analysis
2025     NIHR Health Technology Assessment programme Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial
2025     NIHR Health Technology Assessment programme Supporting self-management with an internet intervention for low back pain in primary care: a RCT (SupportBack 2)
2025     NIHR Health and Social Care Delivery Program Formulating outputs from a mixed-methods study of access to general practice: a series of collaborative stakeholder workshops
2025     NIHR Health Technology Assessment programme Lessons from the PROTECT-CH COVID-19 platform trial in care homes
2025     NIHR Health Technology Assessment programme Stopping anticoagulation for isolated or incidental subsegmental pulmonary embolism: the challenges and lessons from the STOPAPE RCT
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Fibrin sealants and hemostatic matrices in an intraoperative context]
2025     NIHR Health Technology Assessment programme Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis
2025     NIHR Health Technology Assessment programme A personalised health intervention to maintain independence in older people with mild frailty: a process evaluation within the HomeHealth RCT
2025     NIHR Health Services and Delivery Research programme Multiple Symptoms Study 3 – an extended-role general practitioner clinic for patients with persistent physical symptoms: a randomised controlled trial
2025     NIHR Health Services and Delivery Research programme The impact of redeployment during COVID-19 on nurse well-being, performance and retention: a mixed-methods study (REDEPLOY)
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Arthrofibrosis (excessive scarring) in the knee: can surgical procedures reduce movement restrictions and pain?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hip osteoarthritis: can physiotherapy delay or avoid surgery?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capivasertib (breast cancer) – 2nd addendum to Project A24-105]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bulevirtide (chronic hepatitis D, children >= 3 to < 18 years, >= 10 kg) – assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eliglustat (Gaucher disease type 1; children and adolescents) – assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirvetuximab soravtansin (ovarian cancer) – assessment in accordance with §35a (1) Sentence 11 Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Delgocitinib (moderate to severe chronic hand eczema) – addendum to Project A24-107]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capivasertib (breast cancer) – addendum to Project A24-105]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, first line) – addendum to Project A24-97]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial cancer, first line treatment, combination with enfortumab vedotin) – addendum to Project A24-99]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer, first line treatment, combination with pembrolizumab) – addendum to Project A24-98]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotatercept (pulmonary arterial hypertension) – addendum to Project A24-96]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crovalimab (paroxysmal nocturnal haemoglobinuria) – addendum to Project A24-94]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin icodec (type 1 diabetes mellitus) – addendum to Project A24-90]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erdafitinib (urothelial carcinoma) – benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (oesophageal squamous cell carcinoma, second line) – benefit assessment according to § 35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (NSCLC, second line) - benefit assessment according to § 35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (non-squamous NSCLC) - benefit assessment according to §35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (squamous NSCLC, first line) – benefit assessment according to §35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer, adjuvant treatment) – benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linzagolix (endometriosis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Addendum to Project A24-77]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (COPD) - addendum to project A24-79]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ciltacabtagene autoleucel (multiple myeloma, at least one prior therapy) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, suitable for autologous stem cell transplant) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benralizumab (eosinophilic granulomatosis with polyangiitis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) – benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – benefit assessment according to §35a Social Code Book V]
2025     Health Technology Wales (HTW) Implantable tibial neuromodulation devices for treatment of urge urinary incontinence
2025     Health Technology Wales (HTW) Use of advanced electrosurgical bipolar vessel sealing systems during hysterectomy compared to other methods for control of bleeding
2025     Health Technology Wales (HTW) Permanent implant brachytherapy devices for the treatment of locally advanced, unresectable pancreatic cancer
2025     Health Information and Quality Authority (HIQA) National guidelines for the budget impact analysis of health technologies in Ireland
2025     Health Information and Quality Authority (HIQA) National guidelines for the economic evaluation of health technologies in Ireland
2025     Health Information and Quality Authority (HIQA) Protocol: development of a tool for the collection of costs attributable to infectious disease outbreaks in public acute hospitals
2025     Health Information and Quality Authority (HIQA) The management of obesity in adults: protocol for a review of international clinical guidelines
2025     Health Information and Quality Authority (HIQA) The management of acute asthma attack in adults: protocol for a review of international clinical guidelines
2025     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of immunisation against respiratory syncytial virus in Ireland
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Blood testing for cystatin C by immunoturbidimetry]
2025     National Institute for Health and Care Excellence (NICE) Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. NICE interventional procedures guidance 801
2025     National Institute for Health and Care Excellence (NICE) 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites. NICE technology appraisal guidance 1045
2025     National Institute for Health and Care Excellence (NICE) Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 1047
2025     National Institute for Health and Care Excellence (NICE) Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 1046
2025     National Institute for Health and Care Excellence (NICE) Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over. NICE technology appraisal guidance 1050
2025     National Institute for Health and Care Excellence (NICE) Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia. NICE technology appraisal guidance 1049
2025     National Institute for Health and Care Excellence (NICE) Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable. NICE technology appraisal guidance 1048
2025     NIHR Health Technology Assessment programme A group psychological intervention for postnatal depression in British mothers of South Asian origin – the ROSHNI-2 RCT
2025     NIHR Health Technology Assessment programme Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map
2025     NIHR Health Technology Assessment programme Experiences of support to return to work after stroke: longitudinal case studies from RETAKE trial
2025     NIHR Health Technology Assessment programme Gait Rehabilitation for Early rheumatoid Arthritis Trial (GREAT): lessons learnt from a mixed-methods feasibility study and internal pilot trial
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Buccal cell sampling as a source of genetic material]
2025     Austrian Institute for Health Technology Assessment (AIHTA) [Reimbursement models and pricing of digital health technologies and telemonitoring applications – Rapid scoping review]